- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03073148
Evaluation of Tangible Boost Replenishing System
October 23, 2020 updated by: Tangible Science
This study will evaluate Tangible Boost, a new contact lens care product which is designed to replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG.
The Hydra-PEG coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens surface.
This coating improves lens wettability, a common cause of patient discomfort.
Tangible Boost is designed to maintain the wettability of Hydra-PEG lenses throughout the lens lifetime.
Patients can use the Tangible Boost kit to reapply the Hydra-PEG coating each month at home.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77204
- University of Houston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Habitual contact lens wear with a group 3 FDA approved rigid lens material, with 20-50% of subjects wearing corneal lenses
- Willing and able to sign the informed consent form
- 18 years or older
Exclusion Criteria:
- Eye injury or surgery within the 3 months immediately prior to enrollment for this trial
- Pre-existing ocular irritation that would preclude contact lens fitting
- Current enrollment in an ophthalmic clinical trial
- Evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses or use of the accessory solutions, as determined by the investigator
- Any use of medications for which contact lens wear could be contraindicated, as determined by the investigator
- Pregnant women and nursing mothers
- Visual acuity less than 20/20 when best corrected with contact lenses
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Tangible Boost
Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
|
Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
|
|
PLACEBO_COMPARATOR: Control
Participants will treat their lenses with a placebo "Tangible Boost" kit containing saline after 30 days and again after 60 days.
|
Participants will treat their lenses with a placebo "Tangible Boost" kit, which contains saline in place of the Tangible Boost solution.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients With Adverse Event Reports or Discontinuations
Time Frame: Duration of study, 90 +/- 7 days after lens dispense visit.
|
A report of any adverse events or discontinuations that may have occurred.
This measure includes adverse events unrelated to the treatment.
See adverse events section for additional details.
|
Duration of study, 90 +/- 7 days after lens dispense visit.
|
|
Corneal Staining
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
|
Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study.
5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20.
Left and right eye scores were averaged for each subject.
A lower score indicates less corneal damage.
|
1 day after treatment (day 31), final assessment (day 90)
|
|
Visual Acuity
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
|
Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts.
On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.
|
1 day after treatment (day 31), final assessment (day 90)
|
|
Non-invasive Tear Film Break-up Time
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
|
Tear break-up time was measured with the OCULUS Keratograph.
|
1 day after treatment (day 31), final assessment (day 90)
|
|
Number of Participants With Acceptable Lens Fit
Time Frame: final assessment (day 90)
|
Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).
|
final assessment (day 90)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CLDEQ Score
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
|
The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39.
A lower score is indicative of greater comfort.
|
1 day after treatment (day 31), final assessment (day 90)
|
|
Visual Analog Scale (VAS)
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
|
The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.
|
1 day after treatment (day 31), final assessment (day 90)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Maria K Walker, OD MS, University of Houston
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 24, 2017
Primary Completion (ACTUAL)
February 13, 2019
Study Completion (ACTUAL)
February 13, 2019
Study Registration Dates
First Submitted
February 28, 2017
First Submitted That Met QC Criteria
March 2, 2017
First Posted (ACTUAL)
March 8, 2017
Study Record Updates
Last Update Posted (ACTUAL)
November 17, 2020
Last Update Submitted That Met QC Criteria
October 23, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 113133
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contact Lens Solution
-
Alcon ResearchCompletedContact Lens SolutionUnited States
-
Southern California College of Optometry at Marshall...Alcon ResearchCompletedContact Lens Solution ToxicityUnited States
-
Hom, Milton M., OD, FAAOAbbott Medical OpticsUnknownContact Lens Solution ToxicityUnited States
-
Finnsusp Ltd.CompletedAdverse Reaction to Contact Lens SolutionFinland
-
Bausch & Lomb IncorporatedCompletedAdverse Effect of Contact Lens SolutionMalaysia
-
The Hong Kong Polytechnic UniversityOPHTECS CorporationCompleted
-
EV Clinical TrialsCompletedContact Lens Discomfort | Contact Lens | Contact Lens DrynessUnited States
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Aston UniversityCooperVision, Inc.Enrolling by invitationContact Lens Wear | Healthy Participants Study | Contact Lens FitUnited Kingdom
-
Ohio State UniversityCompletedContact LensUnited States
Clinical Trials on Tangible Boost
-
Tangible ScienceBoston SightTerminatedDry Eye | Stevens-Johnson Syndrome | Sjogren's Syndrome | Graft Versus Host Disease in EyeUnited States
-
University of Sao PauloCompleted
-
Vision Service PlanForesight Regulatory Strategies, Inc.CompletedRefractive ErrorsUnited States
-
Tangible ScienceUniversity of California, Davis; Nova Southeastern University; Illinois College...CompletedDry Eye | Dry Eye SyndromesUnited States
-
KU LeuvenJessa Hospital; University Hospital, Ghent; Vrije Universiteit Brussel; Revalidatieziekenhuis...Recruiting
-
National Cancer Institute, EgyptUnknownRadiotherapy Side EffectEgypt
-
GluSense LtdCompleted
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsActive, not recruitingCovid-19 VaccinationNetherlands
-
University Hospitals, LeicesterNovartis; Medical Research Council; Public Health England; National Institute of...CompletedImmunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04InfluenzaUnited Kingdom
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast CarcinomaUnited States